Intercept failed NASH candidate precipitated Alfasigma acquisition
Mohammed Haneefa Nizamudeen After the failure of Intercept Prescribed drugs' (ICPT) Ocaliva (obeticolic acid) for nonalcoholic ...
Read more
Tag: NASH
Sagimet, NASH liver disease drug developer, sets terms for $75M IPO (Pending:SGMT)
Chunumunu Sagimet Biosciences (SGMT), which has been growing therapies for liver illnesses reminiscent of NASH, has ...
Read more